First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome\u2019s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.
In 2022, Oxford Cancer Analytics was voted the company Most Likely to be a Unicorn at that year\u2019s BioEscalator Pitch Battle. Fast forward three years, and the company is well along its growth trajectory. OXcan has graduated from our facility as a fast-scaling diagnostics company, leveraging advanced proteomics and machine learning to develop innovative tests for earlier and more accurate assessment of lung diseases.
In 2024/25, the BioEscalator community achieved remarkable milestones through collaboration with individuals and organisations across the innovation ecosystem. Our annual review, titled \"People and partnerships driving better patient health,\" highlights significant accomplishments and companies such as Oxford Cancer Analytics, with its global perspective. Working with the University of Oxford, alongside tenants and alumni, has been significant in advancing the bioscience industry. This year emphasises our commitment to embracing new ideas while making a meaningful impact.
The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.
The BioEscalator is delighted to welcome Spectre Bio to its start-up community. The company joins us as it transitions from computational research to laboratory-based development, bringing an exciting new immunomodulatory platform to the BioEscalator ecosystem.
Dr Beadle brings a remarkable track record of leading biotechnology companies, guiding teams from early discovery through to successful clinical translation.
U\u2011Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Sim\u00f3n Foundation for Research in Women\u2019s Health, a leading institution advancing scientific excellence in reproductive medicine.
Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.
Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.
Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO\u2019s Inventa building in Oxford\u2019s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster.
Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside\r\nliving cells at base pair resolution for the first time, pioneering a new approach to identify new drug\r\ntargets from human genetics.
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens\u00ae and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX\u2122 as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.
The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.
Leveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.
U-Ploid is today presenting its first scientific abstract, \u201cPreclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,\u201d at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta\u2122 (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.
MediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.
![\"3D](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-nominates-first-preclinical-development-candidate/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n